Compared with placebo intake, intake of tocotrienol by patients with stage 1 or stage 2 breast cancer, and estrogen receptor-positive tumor treated with tamoxifen, is associated with a not statistically significant (P = 0.27) 60% lower risk of mortality, after adjustment for age, ethnicity, stage, and lymph node status. The gene discussed is ESR1; the disease is breast carcinoma.